LPL Financial
SYRS

LPL Financial’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

LPL Financial’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-76,625
Closed -$395K – 5302
2024
Q2 		$395K Buy
76,625
+500
+0.7% +$2.63K ﹤0.01% 4058
2024
Q1 		$407K Sell
76,125
-5,400
-7% -$37.3K ﹤0.01% 3945
2023
Q4 		$635K Sell
81,525
-8,650
-10% -$29.6K ﹤0.01% 3468
2023
Q3 		$356K Sell
90,175
-3,900
-4% -$14.6K ﹤0.01% 3768
2023
Q2 		$296K Buy
94,075
+10,886
+13% +$35K ﹤0.01% 3861
2023
Q1 		$222K Buy
83,189
+42,209
+103% +$164K ﹤0.01% 3963
2022
Q4 		$147K Buy
40,980
+29,145
+246% +$126K ﹤0.01% 4069
2022
Q3 		$76K Buy
11,835
+2,121
+22% +$17.2K ﹤0.01% 4163
2022
Q2 		$94K Sell
9,714
-2,400
-20% -$22.5K ﹤0.01% 4145
2022
Q1 		$144K Buy
12,114
+5,108
+73% +$91.4K ﹤0.01% 3905
2021
Q4 		$228K Buy
7,006
+2,294
+49% +$92.9K ﹤0.01% 3900
2021
Q3 		$211K Buy
4,712
+903
+24% +$44.1K ﹤0.01% 3945
2021
Q2 		$208K Buy
3,809
+1,876
+97% +$111K ﹤0.01% 3880
2021
Q1 		$145K Buy
1,933
+531
+38% +$55.2K ﹤0.01% 3862
2020
Q4 		$152K Buy
+1,402
New +$128K ﹤0.01% 3599

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

LPL Financial's SYRS Position: Q3 2024 in Review

LPL Financial sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 76,625 shares — an estimated $395K sold.

LPL Financial first reported a position in SYRS in Q4 2020 and held it in 15 quarters. The position peaked at $635K in Q4 2023. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • LPL Financial reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • LPL Financial sold 76,625 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $395K.
  • LPL Financial first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • LPL Financial's Syros Pharmaceuticals, Inc. Common Stock position peaked at $635K in Q4 2023.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on LPL Financial's 13F filing for Q3 2024, filed 8 Nov 2024.